Kinnari Patel - 20 May 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
President, Head of R&D and Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
Issuer symbol
RCKT
Transactions as of
20 May 2025
Net transactions value
-$4,944
Form type
4
Filing time
22 May 2025, 16:05:43 UTC
Previous filing
20 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Patel Kinnari President, Head of R&D and Chief Operating Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY /s/ Martin Wilson, as attorney-in-fact for Kinnari Patel 22 May 2025 0001725929

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Sale $4,944 -767 -0.17% $6.45 441,927 20 May 2025 Direct F1, F2
holding RCKT Common Stock 26,774 20 May 2025 By Spouse
holding RCKT Common Stock 104,927 20 May 2025 By Adaptive Technology LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
F3 The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.

Remarks:

President, Head of R&D and Chief Operating Officer